肺癌患者化疗前后S-VEGF、CEA、CA125的检测及临床意义  

作　　者：杨福利[1] 郭本成[1] 

机构地区：[1]莱芜市人民医院,山东省271100

出　　处：《工企医刊》2011年第6期23-24,共2页The Medical Journal of Industrial Enterprise

摘　　要：目的探讨肺癌患者S-VEGF、CEA、CA125表达水平观察其化疗前后的变化,评价其临床意义。方法抽取44例对照组及86例肺癌组外周全血,使用夹心酶联免疫方法测定S-VEGF、CEA、CA125水平。结果肺癌患者S-VEGF、CEA、CA125水平升高化疗有效后仅S-VEGF下降有统计学意义。结论 S-VEGF检测较CEA、CA125对指导临床治疗更有参考价值。objective to explore the lung cancer patients S-VEGF,CEA,CA125 expression level observe the chemotherapy the change of the before and after evaluation of clinical significance.Methods 44 cases extracted in the control group and 86 cases of lung cancer group the comprehensive use blood enzyme league immune method for determining sandwich S-VEGF CEA CA125 levels Results of patients with lung cancer S-VEGF CEA CA125 levels rise after chemotherapy effective only S-VEGF down a statistically significant.Conclusion S-VEGF detection a CEA CA125 to guide clinical treatment more reference value.

关 键 词：肺癌 血清血管内皮生长因子(S-VEGF) 癌胚抗原(CEA) 糖原抗原125(CA125) 

分 类 号：R734.2[医药卫生—肿瘤]